NCT00631943View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Pregabalin (Lyrica) for the Treatment of Nerve Pain

PHASE3CompletedINTERVENTIONAL

Enrollment

112

Participants

Timeline

Start Date

November 30, 2004

Study Completion Date

March 31, 2005

Conditions

Neuralgia

Interventions

DRUG

Pregabalin (Lyrica)

Oral pregabalin (Lyrica) capsules, initial dose of 75 mg twice daily, which could be increased to 300 mg twice daily at the discretion of the investigator. Patients were treated for up to 21 days.

Trial Locations (6)

560054

Pfizer Investigational Site, Bangalore

560 034

Pfizer Investigational Site, Bangalore

400 012

Pfizer Investigational Site, Mumbai

400 007

Pfizer Investigational Site, Maharashtra

600 004

Pfizer Investigational Site, Chennai

600 013

Pfizer Investigational Site, Chennai

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00631943 - A Study to Evaluate the Efficacy and Safety of Pregabalin (Lyrica) for the Treatment of Nerve Pain | Biotech Hunter | Biotech Hunter